Yakup Ergün· @dr_yakupergun · X·· 2 天前评分70
正文 · 原文
#ESMO26 | DESTINY-Breast11
MRI response does not reliably predict pCR. An important limitation for response-guided personalization of neoadjuvant treatment.
1220 浏览 · 14 赞 · 5 转发 · 0 回复
会议摘要
543RO按 Rapid oral: Breast cancer, early stage 对上
DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.org来源：Yakup Ergün · x.com